Navigation Links
Grupo IMO Hosts Symposium on Use of TomoTherapy for Stereotactic Radiosurgery and Stereotactic Body Radiation Procedures : Experts Detail HiArt Platform Advantages for Treatment of Brain, Lung, Pancreatic and Metastatic Cancers
Date:10/15/2008

TomoTherapy Incorporated (NASDAQ: TOMO) announced today that Grupo IMO of Madrid, Spain, recently hosted a symposium on the clinical use of the HiArt treatment system for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). Symposium speakers highlighted the HiArt system’s inherent suitability for stereotactic procedures with respect to dose conformality and homogeneity; presented clinical work on a variety of intra- and extracranial cases; and discussed future research goals.

MADISON, Wis. (Business Wire EON) October 15, 2008 -- According to Jef Van Dam, TomoTherapy EMEA General Manager: "We are extremely pleased that Grupo IMO hosted this symposium highlighting the excellent clinical stereotactic work being done by TomoTherapy customers. We are eager to demonstrate how the clinical applications of TomoTherapy continue to grow as new treatment possibilities are explored by our clinical partners."

The 'Symposium on Tomo-Radiosurgery' included presentations from Dr. Jos Sambls, neurosurgeon and Grupo IMO president, Dr. Jos Miguel Delgado, clinical physicist and technical director for Grupo IMO, and Dr. Matthias Uhl, radiation oncologist, Heidelberg University Clinic, Heidelberg, Germany. The event was held in conjunction with the Spanish Radiosurgery Conference.

Peter Hoban, Ph.D., TomoTherapy senior product managerand medical physicist, began the program by outlining features that make the HiArt system ideal for providing stereotactic treatments: "TomoTherapy's integrated imaging and delivery platform allows one simple process to be used for both stereotactic and intensity-modulated radiation therapy (IMRT) treatments. The system clearly lends itself to a diverse range of clinical indications, as evidenced by the presentations of Drs. Sambls, Delgado and Uhl."

  • Sambls and Dr. Delgado presented technical and clinical stereotactic work using the TomoTherapy HiArt treatment system and discussed Grupo IMO's research goals for the future.

Said Dr. Sambls: "TomoTherapy HiArt allows the development of new techniques for treating brain tumors with maximum precision. In this sense, we have achieved great preliminary results with what we call Tomo-Radiosurgery, fundamentally with regard to irregularly shaped brain tumors, brain metastases and tumors located close to critical organs such as the optic nerves and the brain stem. Another example is the treatment of acoustic neurinoma. We believe TomoTherapy's especially homogenous dose distribution capabilities may help to spare sensitive auditory nerve tissue."

  • Matthias Uhl explained how University Clinic Heidelberg has expanded its own use of the TomoTherapy HiArt system to include stereotactic treatments.

"We are applying TomoTherapy to SBRT for early-stage lung cancer and also multiple metastases in the brain and liver," said Dr. Uhl. "Treating multiple lesions simultaneously results in a reduced amount of timethe patient spends in the treatment room compared with conventional treatment alternatives."

About Grupo IMO

Grupo IMO is the first facility in Spain to offer TomoTherapy radiation treatments. More than 300 patients have been treated on the TomoTherapy HiArt System since April 2006. Established in 1991, Grupo IMO has the largest autonomous network of ten reference centers for cancer treatment using radiotherapy and radiosurgery techniques in Spain.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy HiArt treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The HiArt treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

2008 TomoTherapy Incorporated. All rights reserved.TomoTherapy, the TomoTherapy logo and HiArt are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.

Read the full story at http://www.prweb.com/releases/grupo_imo/stereotactic_body/prweb1480034.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Grupo Casa Saba Announces Sales and Operating Income Increased 14.05% and 13.45%, Respectively
2. Grupo Casa Saba Announces Fourth Quarter 2007 Results
3. Grupo Casa Saba Announces Third Quarter 2007 Results
4. Pennsylvania Breast Cancer Coalition Hosts Annual Conference
5. Baird Hosts Small Cap Health Care Conference : Senior Healthcare Distribution & Services Research Analyst Eric Coldwell Shares Insights on Sector
6. Health Insurance Industry Hosts Roundtable Discussion on Health Care Reform in Albuquerque
7. RMA of Michigan Hosts 1st Metro Detroit Area Hope Uncorked: Exclusive Wine Tasting Event To Benefit Fertile Hope
8. Alameda County Hosts National Initiative to Reduce Health Disparities
9. Hospira Hosts Conference Call for Second-Quarter 2008 Earnings
10. National Medical Association Hosts the 2008 Annual Convention and Scientific Assembly
11. Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Grupo IMO Hosts Symposium on Use of TomoTherapy for Stereotactic Radiosurgery and Stereotactic Body Radiation Procedures :  Experts Detail HiArt Platform Advantages for Treatment of Brain, Lung, Pancreatic and Metastatic Cancers 
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and ... out for each of his children. “The Angel” is the creation of published author, ... New York City, and impassioned writer. , When asked of her new book, Marjorie ...
(Date:1/20/2017)... ... ... “Journey to Christmas:” a beautiful and enchanting tale that teaches children the true meaning of ... three in Oklahoma City, and a devoted woman of faith. , “Becoming a parent ... the back of my mind for years, but actually doing it might have been a ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Learning Management System: an On-demand E-learning system for Clinical and Regulatory education ... that is based on Aerolib`s successful education methodology of Disease Specific Documentation ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... innovators, engineers, and scientists from around the world, announces the launch of its ... quick and easy portal to research breakthroughs and trending news, vital information on ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... development solutions for drugs, biologics and consumer health products, today announced that it ... Gattefossé, the leader in innovative excipients and drug delivery solutions to health industries ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... The global  pacemaker market  is expected to reach USD 12.3 billion ... heightening prevalence of cardiac conditions coupled with the availability of medical coverage is ... enhancements in these devices are supporting the expansion of this vertical. ... ... Grand View Research Logo ...
(Date:1/19/2017)... The Global Therapy Partnering Terms and Agreements since 2010 ... agreements entered into by the world,s leading healthcare companies. ... by value - Deals listed by company A-Z, industry ... provides understanding and access to the partnering deals and ... The report provides an analysis of partnering deals. ...
(Date:1/19/2017)... Jan. 18, 2017 The drug delivery technology ... 2021 from USD 1,179.20 billion in 2016, at a ... prevalence of chronic diseases, increasing demand for biologics, technological ... the growth of this market. Whereas, self-administration & home ... offer significant growth opportunities for players operating in this ...
Breaking Medicine Technology: